Business Wire

Forecasting, Monitoring and KI – Swarm Intelligence for the Energy Transition at EM-Power Europe

1.6.2023 12:26:00 EEST | Business Wire | Press release

Share

The energy transition does not just change the energy generation technologies we use, but also requires the power grids to be updated. Today, instead of a dozen large-scale power plants, an enormous swarm of power plants all feed into our grid: Several thousand wind farms and over 2.6 million PV systems have been installed in Germany alone – and there is a steep upward trend. This makes our power generation weather dependent: On windless or cloudy days, the energy supply may not match the demand, leading to bottlenecks – or worse – blackouts. To keep the grid frequency at a stable 50.2 hertz, grid operators need yield forecasts. Artificial intelligence (AI) helps process this highly complex information and integrate it into the energy system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005572/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

EM-Power Europe Exhibition (Photo: Solar Promotion GmbH)

With millions of solar installations, wallboxes and heat pumps, home storage systems and car batteries that will someday be able to feed electricity back into the grid, today’s utility grid system is already so complex that utilities and grid operators would be lost without their digitalized systems. The more they know about when, where and how much electricity is being produced, fed into the grid and demanded by consumers, the more precisely can they match their supply to the demand. This also makes it more profitable, as making up for shortages is expensive. When generation does not cover consumption within a balancing group, grid operators are forced to pay balancing costs. The more accurate the weather and yield forecasts for wind and solar power plants, the more successful the companies will be. Individuals who want to optimize their self-consumption using batteries or controllable consumers like e-cars or heat pumps also require forecasts to determine what the electricity should be used for. The same goes for the energy management of buildings.

Weather forecast for the energy industry

At EM-Power Europe, the international exhibition for energy management and integrated energy solutions, companies from all around the world present their digitalization concepts as well as innovative technologies and services for the optimized grid of the future. “Machine learning and AI play a crucial role in the irradiation forecast,” Jan Remund, Head of the Department for Energy and Climate at Meteotest AG, a Swiss weather forecast provider, explains. The company is able to predict cloud movements by combining physical models with self-learning algorithms based on satellite images. “The accuracy for the next few hours is quite high. The longer the time span, the less accurate the forecasts are,” says Remund. His company collects irradiation and temperature data and uses it to make analyses, profiles and forecasts that can be integrated into the respective PV monitoring or control software. Companies can use the weather forecasts as a basis for calculating solar irradiation using dedicated software, or they can buy such calculations. Grid operators rely on irradiation forecasts to balance the grid’s feed-in and feed-out based on the production and demand forecasts.

Meteocontrol, a monitoring and forecast specialist company from the South of Germany makes yield calculations based on the data of different weather forecast providers. The company also investigates how aerosols like ash or sand affect cloud formation. “On March 3 and 4, 2021, our research project “PermaStrom” exemplified how important this issue is,” says Stijn Stevens, CEO of meteocontrol. “There was a lot of Saharan dust in Europe on those two days. Thanks to optimized forecasts, about three million euros were saved in balancing energy costs in Germany alone.

The integration of smart applications and AI into the utility grid system creates digital swarm intelligence. By combining the power generation and consumption forecasts with the capacity of conventional power plants, grid operators can predict when and where the grids and transformers will reach their maximum capacity. This allows them to take the necessary precautions.

Prosumers: underestimated key players

Prosumers will play a vital role in the energy systems of the future: For instance, private individuals and households can feed excess electricity from their e-cars into the grid, contributing significantly to its stability. The company Hive Power already offers software for the intermittent feedback of electricity from car batteries into the grid, called Vehicle-to-Grid. Artificial intelligence helps here, too: The software learns when vehicles are in use and when they are not, allowing it to feed electricity into the grid when there is excess capacity. Prosumers could earn up to 1,000 euros per year in this way.

Smart technology for buildings

Weather and yield forecasts are also crucial for the energy management of buildings. Heat pumps can charge the heating storage device when the sun is shining, and feed the energy into the heating circuit in the evening. With the right software, heat pumps can apply the yield forecasts provided by the energy management system to their operating schedules. This prevents heat pumps from using grid-supplied electricity to heat thermal energy storage when sufficient solar energy is expected within the next hour. Another possibility is to time the charging of electric vehicles in a way that maximizes the share of solar power. Solar-Log’s systems are based on the same principle. They provide optimal electricity self-consumption for office buildings and industrial facilities through battery storage and flexible loads, such as heat pumps or charging stations.

Apart from the aforementioned companies, numerous other exhibitors will present their solutions for weather and yield forecasts, grid connection, monitoring and analysis software at EM-Power Europe in Munich from June 14–16. Visitors can learn more about the possibilities of forecasting and monitoring systems at the EM-Power Forum session “Forecasting & monitoring: Always a step ahead” (“Forecasting & Monitoring: Immer einen Schritt voraus sein”).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contacts

Peggy Zilay
Spokesperson
The smarter E Europe
+49 7231 58598-240
zilay@solarpromotion.com

Juliane Heermeier
Account Manager
+49 151 41482446
juliane.heermeier@fischerappelt.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye